Cumberland Pharmaceuticals Inc. CPIX
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 18.39M | 18.39M | 17.95M | 18.74M | 28.21M |
| Total Other Revenue | 4.13M | 4.13M | 1.33M | 1.33M | 1.33M |
| Total Revenue | 22.52M | 22.52M | 19.28M | 20.07M | 29.54M |
| Cost of Revenue | 3.23M | 3.23M | 2.97M | 3.30M | 5.01M |
| Gross Profit | 19.29M | 19.29M | 16.31M | 16.77M | 24.53M |
| SG&A Expenses | 22.23M | 22.11M | 19.41M | 19.48M | 23.83M |
| Depreciation & Amortization | 2.04M | 2.03M | 2.48M | 2.55M | 3.64M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.90M | 31.70M | 28.93M | 29.45M | 36.82M |
| Operating Income | -9.39M | -9.18M | -9.65M | -9.38M | -7.29M |
| Income Before Tax | -9.20M | -8.94M | -9.50M | -9.08M | -7.18M |
| Income Tax Expenses | 38.50K | 40.30K | -39.90K | -34.20K | -28.50K |
| Earnings from Continuing Operations | -9.23 | -8.98 | -9.46 | -9.04 | -7.15 |
| Earnings from Discontinued Operations | 1.83M | 6.12M | 6.12M | 6.12M | 3.86M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 17.20K | 28.70K | 9.50K | -5.90K | 16.60K |
| Net Income | -7.38M | -2.84M | -3.33M | -2.93M | -3.28M |
| EBIT | -9.39M | -9.18M | -9.65M | -9.38M | -7.29M |
| EBITDA | -5.00M | -5.03M | -5.05M | -4.70M | -2.50M |
| EPS Basic | -0.49 | -0.19 | -0.23 | -0.21 | -0.24 |
| Normalized Basic EPS | -0.26 | -0.25 | -0.28 | -0.27 | -0.32 |
| EPS Diluted | -0.49 | -0.19 | -0.24 | -0.22 | -0.25 |
| Normalized Diluted EPS | -0.26 | -0.25 | -0.28 | -0.27 | -0.32 |
| Average Basic Shares Outstanding | 59.84M | 59.82M | 58.83M | 57.93M | 57.08M |
| Average Diluted Shares Outstanding | 59.84M | 59.82M | 58.83M | 57.93M | 57.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |